| 2026-08-13 | Press release | Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesi |
| 2026-08-07 | Presentation | Biomea Fusion Corporate Presentation August 2026 |
| 2026-08-06 | Presentation | Biomea Fusion At-a-Glance Presentation |
| 2026-08-05 | Press release | Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights |
| 2026-06-22 | Presentation | Biomea Fusion Corporate Presentation June 2026 |
| 2026-06-05 | Press release | Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 8 |
| 2026-06-03 | Press release | Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with S |
| 2026-05-12 | Press release | Biomea Fusion to Participate at Upcoming Investor Conferences |
| 2026-05-11 | Press release | Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights |
| 2026-05-05 | Press release | Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Se |
| 2026-04-27 | Press release | Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Im |
| 2026-03-31 | Press release | Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Fail |
| 2026-03-24 | Press release | Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights |
| 2026-03-14 | Press release | Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Te |
| 2026-02-19 | Press release | Biomea Fusion to Participate at Upcoming Investor Conferences |
| 2026-01-12 | Press release | Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones |
| 2025-12-17 | Press release | Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 2025-12-09 | Press release | Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025 |
| 2025-12-05 | Press release | Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovas |
| 2025-12-01 | Press release | Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Car |
| 2025-11-24 | Press release | Biomea Fusion to Participate at Upcoming Investor Conferences |
| 2025-11-05 | Press release | Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025 |
| 2025-10-30 | Press release | Biomea Fusion to Present Poster Presentations at ObesityWeek®2025 |
| 2025-10-27 | Press release | Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist |
| 2025-10-21 | Press release | Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series |
| 2025-10-06 | Press release | Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-C |
| 2025-09-16 | Press release | Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in |
| 2025-06-23 | Press release | Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American D |
| 2025-06-18 | Press release | Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrati |
| 2025-06-13 | Press release | Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory A |
| 2025-05-14 | Press release | Biomea Fusion’s BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Ac |
| 2025-02-27 | Press release | Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments f |
| 2025-01-07 | Press release | Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study |
| 2025-01-06 | Press release | Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
| 2024-12-17 | Press release | Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabet |
| 2024-12-16 | Press release | Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type |
| 2024-12-14 | Presentation | Combination of Icovamenib and GLP-1-Based Therapeutic Agents Improves Beta Cell Function and Insulin Secretion Oral Pres |
| 2024-12-14 | Presentation | Unlocking the Potential of Menin Inhibition: Icovamenib and a look into the Future of Diabetes Management Breakfast Symp |
| 2024-12-12 | Press release | Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Di |
| 2024-12-10 | Presentation | Investigating the Effects of Icovamenib on Poorly Managed Severe Insulin-Deficient Diabetes (SIDD): Insights from COVALE |